Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christy A Russell

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Current Oncology Reports|December 21, 2002
Adjuvant systemic therapy for lymph node-negative breast cancer less than or equal to 1 cmChristy A Russell
Clinical Advances in Hematology & Oncology : H&O|February 6, 2015
Molecular profiling for DCISChristy A Russell
Current Women'S Health Reports|July 16, 2002
Adjuvant systemic therapy for lymph node-negative breast cancer less than or equal to 1 cmChristy A Russell
American Journal of Surgery|March 4, 2014
Personalized medicine for breast cancer: it is a new day!Christy A Russell
Managed Care Interface|December 29, 2007
Letrozole as adjuvant therapy for postmenopausal women with early breast cancerChristy A Russell
Oncology (Williston Park, N.Y.)|February 3, 2005
Gemcitabine and platinum-based chemotherapy in metastatic breast cancerHsiao C Li, Christy A Russell
Journal of Surgical Oncology|July 14, 2011
Ductal carcinoma in situ (DCIS) of the breast: perspectives on biology and controversies in current managementIsaac Schmale, Stephen Liu, Jessica Rayhanabad, et al.
Journal of Surgical Oncology|February 27, 2010
Neoadjuvant therapy for breast cancerStephen V Liu, Laleh Melstrom, Kathy Yao, et al.
NPJ Breast Cancer|August 30, 2018
Clinical relevance of the 21-gene Recurrence Score<sup>®</sup> assay in treatment decisions for patients with node-positive breast cancer in the genomic eraEleftherios P Mamounas, Christy A Russell, Anna Lau, et al.
American Journal of Ophthalmology Case Reports|March 6, 2018
The tipping point: Tamoxifen toxicity, central serous chorioretinopathy, and the role of estrogen and its receptorsNicole Koulisis, Stavros N Moysidis, Lisa C Olmos de Koo, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Current Oncology Reports|December 21, 2002
Adjuvant systemic therapy for lymph node-negative breast cancer less than or equal to 1 cmChristy A Russell
Clinical Advances in Hematology & Oncology : H&O|February 6, 2015
Molecular profiling for DCISChristy A Russell
Current Women'S Health Reports|July 16, 2002
Adjuvant systemic therapy for lymph node-negative breast cancer less than or equal to 1 cmChristy A Russell
American Journal of Surgery|March 4, 2014
Personalized medicine for breast cancer: it is a new day!Christy A Russell
Managed Care Interface|December 29, 2007
Letrozole as adjuvant therapy for postmenopausal women with early breast cancerChristy A Russell
Oncology (Williston Park, N.Y.)|February 3, 2005
Gemcitabine and platinum-based chemotherapy in metastatic breast cancerHsiao C Li, Christy A Russell
Journal of Surgical Oncology|July 14, 2011
Ductal carcinoma in situ (DCIS) of the breast: perspectives on biology and controversies in current managementIsaac Schmale, Stephen Liu, Jessica Rayhanabad, et al.
Journal of Surgical Oncology|February 27, 2010
Neoadjuvant therapy for breast cancerStephen V Liu, Laleh Melstrom, Kathy Yao, et al.
NPJ Breast Cancer|August 30, 2018
Clinical relevance of the 21-gene Recurrence Score<sup>®</sup> assay in treatment decisions for patients with node-positive breast cancer in the genomic eraEleftherios P Mamounas, Christy A Russell, Anna Lau, et al.
American Journal of Ophthalmology Case Reports|March 6, 2018
The tipping point: Tamoxifen toxicity, central serous chorioretinopathy, and the role of estrogen and its receptorsNicole Koulisis, Stavros N Moysidis, Lisa C Olmos de Koo, et al.
Pageof 3